NTR-101

NTR-101 is an **oral bacteriophage therapy** developed for the treatment of **acute alcohol-associated hepatitis (AH)**, specifically targeting virulent, cytolysin-positive strains of **Enterococcus faecalis**. These pathogenic strains are implicated in exacerbating liver injury in AH through bacterial translocation and toxin release, contributing to severe liver inflammation and poor outcomes. NTR-101 employs natural bacteriophages with specificity for cytolysin-positive E. faecalis, aiming to reduce disease progression by eliminating this bacterial trigger. Its use is being investigated particularly in patients unresponsive to standard treatments such as corticosteroids or those failing antibiotics, offering a targeted, non-antibiotic alternative leveraging the precision of phage therapy[1][3][7].